4 ms·

"Two doses of the Pfizer/BioNTech or Oxford/AstraZeneca vaccine are estimated to be 96% and 92% effective against hospitalisation with the Delta variant, respec

"Two doses of the Pfizer/BioNTech or Oxford/AstraZeneca vaccine are estimated to be 96% and 92% effective against hospitalisation with the Delta variant, respectively Vaccine effectiveness against symptomatic cases with the Delta variant is estimated to be 88% after both doses of the Pfizer/BioNTech vaccine and 67% after both doses of the Oxford/AstraZeneca vaccine." Source: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19latestinsights/vaccines#vaccine-effectiveness https://www.ons.gov.uk/peoplepopulationandcommunity/healthan...

logicchains 5y ago
"A full course of the Pfizer-BioNTech vaccine is 64% effective at preventing symptomatic Covid-19, according to an early study by Israel’s health ministry reported Monday, much lower than previous estimates of nearly 90%. The vaccine still appears to be highly effective, 93%, at preventing serious illness and hospitalization, the data shows, though this is also slightly lower than earlier studies suggested and for other variants." Source: https://www.forbes.com/sites/roberthart/2021/07/06/pfizer-shot-much-less-effective-against-delta-israel-study-shows---heres-what-you-need-to-know-about-variants-and-vaccines/?sh=7527b24d3071 https://www.forbes.com/sites/roberthart/2021/07/06/pfizer-sh...
rossdavidh 5y ago
Also important and useful, but that's a different percentage. That's the percentage reduction as compared to a non-vaccinated (hopefully otherwise matched) group. This is the percentage of the population (here, healthcare workers) who got it. Which, frankly, is the percentage I care more about, personally, although for Phase 3 testing of vaccines of course the percentage you're talking about is what matters. Given that my daughter, who got the Pfizer vaccine, is unlikely to be exposed to covid-19 virus MORE often than a typical healthcare worker, this is good news. I wish we had as good a study for Moderna and J&J, but hopefully we get one soon.

logicchains 5y ago

"A full course of the Pfizer-BioNTech vaccine is 64% effective at preventing symptomatic Covid-19, according to an early study by Israel’s health ministry reported Monday, much lower than previous estimates of nearly 90%. The vaccine still appears to be highly effective, 93%, at preventing serious illness and hospitalization, the data shows, though this is also slightly lower than earlier studies suggested and for other variants." Source: https://www.forbes.com/sites/roberthart/2021/07/06/pfizer-shot-much-less-effective-against-delta-israel-study-shows---heres-what-you-need-to-know-about-variants-and-vaccines/?sh=7527b24d3071 https://www.forbes.com/sites/roberthart/2021/07/06/pfizer-sh...

rossdavidh 5y ago

Also important and useful, but that's a different percentage. That's the percentage reduction as compared to a non-vaccinated (hopefully otherwise matched) group. This is the percentage of the population (here, healthcare workers) who got it. Which, frankly, is the percentage I care more about, personally, although for Phase 3 testing of vaccines of course the percentage you're talking about is what matters. Given that my daughter, who got the Pfizer vaccine, is unlikely to be exposed to covid-19 virus MORE often than a typical healthcare worker, this is good news. I wish we had as good a study for Moderna and J&J, but hopefully we get one soon.